Abuse (NIDA), and is utilized under the supervision of a study physi-cian. The aim of this study is to examine the overall health status of 4 of the7survivingpatientsintheprogram.Thisprojectprovidesthefirstop-portunity to scrutinize the long-term effects of cannabis on patients whohaveusedaknowndosageofastandardized,heat-sterilizedquality-con-trolled supply of low-grade marijuana for 11 to 27 years.Results demonstrate clinical effectiveness in these patients in treatingglaucoma,chronicmusculoskeletalpain,spasmandnausea,andspasticityof multiple sclerosis. All 4 patients are stable with respect to theirchronic conditions, and are taking many fewer standard pharmaceuticalsthan previously.Mild changes in pulmonary function were observed in 2 patients,while no functionally significant attributable sequelae were noted in anyother physiological system examined in the study, which included: MRIscans of the brain, pulmonary function tests, chest X-ray, neuropsy-chological tests, hormone and immunological assays, electroencepha-lography, P300 testing, history, and neurological clinical examination.These results would support the provision of clinical cannabis to agreater number of patients in need. We believe that cannabis can be asafe and effective medicine with various suggested improvements in theexisting Compassionate IND program.
[Article copies available for a fee from The Haworth Document Delivery Service: 1-800-HAWORTH. E-mail ad-dress:<firstname.lastname@example.org>Website:<http://www.HaworthPress.com>
2002 by The Haworth Press, Inc. All rights reserved.]
Cannabis, medical marijuana, hashish, investigationalnew drug, compassionate use, NIDA, FDA, herbal medicine, analgesia,spasticity, chronic pain, glaucoma, multiple sclerosis, epidemiology,history of medicine, drug policy
The Missoula Chronic Clinical Cannabis Use Study was proposed toinvestigatethetherapeuticbenefitsandadverseeffectsofprolongeduseof “medical marijuana” in a cohort of seriously ill patients approvedthrough the Compassionate Investigational New Drug (IND) programof the Food and Drug Administration (FDA) for legal use of cannabisobtained from the National Institute on Drug Abuse (NIDA), under thesupervision of a study physician. The aim was to examine the overallhealth status of 8 surviving patients in the program. Four patients wereabletotakepart,whilethreewishedtoremainanonymous,andonewas
4 JOURNAL OF CANNABIS THERAPEUTICS